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Abstract 
Background: The liver is a common site for malignant metastases. Surgical metastatic resection, ablative therapies, and 
external beam radiation therapy (EBRT) all have advantages and limitations. Preliminary reports reveal SBRT treats 
hepatic metastases with limited toxicities. We reviewed our institution’s SBRT experience for the treatment of liver 
metastases to assess toxicity and outcomes. 
Methods: Hepatic metastases treated with SBRT were retrospectively reviewed from 2008-2010. Computed tomography 
(CT) identified tumor volume prior to SBRT, local recurrence and out-of-field progression after SBRT. Study endpoints 
were local recurrence, toxicity, and overall survival. 
Results: Thirty-three patients had 37 liver metastases treated with a median SBRT dose of 30Gy. Median follow-up was 
8.1 months. Five lesions (13.5%) locally recurred after a median of 10.6 months. Seventeen patients had out-of-field 
progression (15 liver, 6 systemic) after a median of 5.1 months. Overall 23.5-month survival was 45.5%. Five patients 
reported nausea and seven reported pain after SBRT. There were no grade 4-5 toxicities or cases of liver failure. 
Conclusion: SBRT is safe and well tolerated in patients with hepatic metastases. SBRT offers a local therapy with limited 
toxicities to patients with lesions not amenable to traditional ablative, surgical, or regional therapies. 
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Introduction 
The liver is a common site of metastasis for many tumors, especially from the gastrointestinal tract. Select 
patients with isolated liver metastases may benefit from aggressive therapy including surgical resection of 
hepatic disease [1-4]. Five-year survival rates of patients after hepatic metastatic surgical resection are 
30-40% in colorectal cancer [4, 5]. Five-year survival rates for select patients treated with surgical 
resection for liver metastases are 20-33% in breast cancer [6, 7] and 9-38% in ovarian cancer [8,9]. While 
hepatic metastectomy has lengthened survival and cured select patients, the majority of patients are not 
candidates for surgical resection [10, 11]. In colorectal cancer, less than 20% of patients are candidates for 
surgical resection [12]. 
While surgical resection of hepatic metastases is the preferred method of treatment, the management of 
patients with unresectable hepatic lesions is less well defined and multiple opinions exist. Non-resectional 
therapies including cryotherapy, microwave ablation, and radiofrequency ablation have been developed to 
treat patients with hepatic metastatic disease not amenable to surgical resection [13]. These modalities 
have demonstrated some success improving local recurrence and hold potential for prolonged survival. 
Cryotherapy has been shown to have a 12-39% local recurrence rate and a 17% five-year survival rate 
[13-16]. Microwave ablation is associated with a 5-13% local recurrence rate and a 16% five-year survival 
rate [13, 17, 18]. Studies on radiofrequency ablation report a 10-31% local recurrence rate and a 24% 
five-year survival rate [13, 19-21]. Prior literature has found higher local recurrence rates and higher rates 
of morbidity for larger hepatic lesions treated with ablative techniques [22-26]. Additionally, there are 
limitations to ablative therapy when the metastasis is centrally located [22]. Advantages of these therapies 
include hepatic parenchymal preservation, less physiological stress, and less invasive strategies [13]. 
While ablative therapies may alter the natural history of these cancers, the overall five-year survival rate 
remains less than 25% for all three modalities likely secondary to the advanced nature of disease in the 
patients treated [13]. 
External beam radiation therapy (EBRT) directed at liver metastases has had limited success with a 
high local recurrence rate, poor survival rate, and toxicities [27-29]. Normal hepatocytes are sensitive to 
radiation doses above 35 Gy [28, 29]. EBRT is associated with significant damage to surrounding healthy 
liver parenchyma when attempting to deliver effective radiation doses to the tumor, therefore limiting 
therapeutic doses to the cancer [20, 30]. Three-dimensional conformal radiotherapy has made it possible 
to deliver higher doses of radiation to a specified hepatic location without increasing the dose to the 
surrounding liver volume [31]. However patients with radiation-induced liver disease, who received 
higher doses of 3-D radiotherapy, had a significantly higher probability of normal tissue complications 
[32, 33].  
Stereotactic body radiation therapy (SBRT) addresses the limitations of conventional radiation (EBRT) 
when treating liver metastases [34-36]. SBRT is robotic radiosurgery that delivers radiation via a linear 
accelerator mounted on a robotic arm that tracks and ablates the metastatic target in real time. As opposed 
to conventional EBRT, SBRT uses improved immobilization and tracking in order to deliver high doses of 
radiation with high degrees of precision; fiducial markers are placed in or near the target lesion to account 
for respiratory motion [34]. SBRT has been utilized to treat cancer in many other sites aside from the liver. 
The higher doses delivered by SBRT (up to 40 Gy per fraction) compared to conventional EBRT (2 Gy per 
fraction) result in more efficient cell kill while improving targeting and allowing for less radiation 
delivered to nearby normal tissue. This allows for delivery of high dose radiation to the metastatic lesion 
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and a minimal dose to surrounding tissues [37, 38].  
Radiation is delivered based on the biological effective dose (BED), which is a mathematical concept 
used to translate the improved efficiency (decreased ability for DNA repair) seen with higher doses of 
radiation given in smaller numbers of fractions. For example, 60 Gy in three 20 Gy fractions is the 
equivalent of 75 fractions of 2 Gy per fraction given every day using the BED equation: BED (2 Gy 
equivalent) = dose * fractions (dose+10) / (12) where we use an alpha/beta ratio of 10 (conventional for 
tumors).  
With the development of SBRT, metastatic liver lesions can be treated with therapeutic radiation doses 
without traditional toxicity, therefore this therapy may benefit patients that are not candidates for 
traditional surgical resection of liver metastases. The goal of this study was to review our institution’s 
early experience with SBRT to treat liver metastases in patients whose lesions were not amenable to 
surgical resection or were considered poor surgical candidates to determine if SBRT can effectively treat 
these patients with limited toxicity. 
Methods 
We conducted a retrospective review of an IRB approved prospective database to assess the outcomes of 
patients treated at our institution with SBRT for liver metastases. Inclusion criteria were all patients 
treated with SBRT for liver metastasis from June 2008 to June 2010. Metastatic lesions were included 
from any location within the liver. All included patients were discussed at multi-disciplinary tumor 
conference. Patients selected for treatment with SBRT were not considered candidates for surgical 
resection secondary to tumor location, comorbidities, clinical presentation, or extent of disease.  
The patients in this study received SBRT by the Cyberknife® Robotic Radiosurgery System (Accuray, 
Sunnyvale, California). It is an image-guided SBRT system that uses a linear accelerator mounted on a 
robotic arm with a respiratory compensation system called Synchrony® Respiratory Tracking System 
(Accuray, Sunnyvale, California) to guide the robot in applying radiation to the targeted lesion [39]. 
Pre-treatment imaging using computed tomography (CT) and MRI were used to identify the gross tumor 
volume. All patients had fiducials placed to mark the location of the metastases and account for 
respiratory motion. Treatment planning, length of treatment, and radiation doses were determined by the 
radiation oncologist overseeing treatments. 
Following SBRT therapy, repeat CT scans and laboratory blood work were completed to identify 
treatment response. An attending radiologist reviewed these CT scans to evaluate local tumor control, one 
of our primary study endpoints. Increased enhancement or tumor progression within the SBRT treatment 
field on follow up CT scan indicated in-field local tumor recurrence. Out of SBRT field hepatic 
recurrences were defined as regional recurrence and extrahepatic recurrence was defined as systemic 
progression. Both regional recurrence and systemic progression were also monitored via follow up CT 
scans. A Kaplan-Meier curve was used to evaluate local control rates and actuarial survival.  
Medical records were reviewed to collect patient demographic data including age and sex. Tumor 
characteristics analyzed included tumor primary, TNM staging, number of liver metastases, size and 
location of liver metastases, and presence of extra-hepatic metastasis. Prior treatments for their primary 
malignancies including surgery, chemotherapy, and radiation therapy were recorded. 
The primary study endpoints were local tumor control, survival, and toxicity secondary to SBRT. 
Toxicities evaluated included nausea, emesis, post-therapy pain, and liver failure. The Common 
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Terminology Criteria for Adverse Events (CTCAE) was used to define toxicity grade following SBRT for 
liver metastases.  
Fisher’s Exact Test, two-tailed Student’s t-Test, and Wilcoxon Rank Sum Test and were used to 
compare categorical and continuous variables. A p-value ≤ 0.05 was considered statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Clinical Characteristics of All Patients Prior to SBRT (Table 1) 
Thirty-three patients had 37 liver metastases treated with SBRT between June 2008 and June 2010 in the 
first 2 years of experience at our institution using SBRT. Clinical characteristics of the patients treated 
with SBRT for liver metastases prior to therapy are reported in Table 1. Our patient population was 48.5% 
male (16 males, 17 females) with a median age of 58.3 (27.9-85.3) years old at the time of SBRT. Of the 
treated metastases, 28 were located in the right lobe and 9 in the left lobe. The median diameter of the 
metastatic liver lesions was 4.0cm (1.6 to 13.9 cm). Twenty-nine patients (87.9%) were treated for solitary 
hepatic metastatic lesions and four patients (12.1%) were treated for two hepatic metastatic lesions with 
SBRT. Sixteen of 33 patients (48.5%) had multiple liver metastases. There was a median of 3 hepatic 
metastases (1-5 hepatic metastases) per patient and 1.3 ± 0.8 metastases were treated with SBRT. A 
median time period from diagnosis of primary cancer to SBRT was 33.3 months (5.7-320 months). A 
median of 13.5 months (1.6-109 months) had elapsed between the diagnosis of liver metastases and SBRT. 
Colorectal cancer was the predominant primary tumor type identified in 39.4% of patients (13 patients). 
The remaining tumor primaries were varied and included 4 ovarian, 4 breast, 3 melanoma, 2 liver, 2 lung, 
1 gastric, 1 cholangiocarcinoma, 1 pancreas, 1 anal, and 1 bladder. 
Prior to SBRT, the majority of patients (27 of 33, 81.8%) had undergone surgical resection of their 
primary tumor and chemotherapy for treatment of metastatic disease (26 of 33, 78.8%). Additionally, 15 
Table 1 Clinical Characteristics of all Patients (n=33) Prior to SBRT for Liver Metastases (n=37) 
Age (years) 58.3 (27.9-85.3)* 
Gender (male) 16 (48.5%) 
Time from Diagnosis to SBRT (months) 33.3 (5.7-320) 
Time from Metastases Diagnosis to SBRT (months) 13.5 (1.6-109) 
Hepatic Lobe (Right) 28 (75.7%) 
Tumor Diameter (cm) 4.0 (1.6-13.9) 
Number of Hepatic Metastases 3 (1-5) 
Multiple Hepatic Metastases 16 (48.5%) 
Prior Primary Surgical Resection  27 (81.1%) 
Prior Chemotherapy 26 (78.8%) 
Prior Radiation 15 (45.5%) 
* Median (Range) 
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of 33 patients (45.5%) had radiation therapy to their primary tumor site prior to undergoing SBRT for 
liver metastases. Fifteen patients (45.5%) had extra-hepatic disease located in the lung (4, 26.7%), colon 
(3, 20%), mediastinum (2, 13.3%), spine (2, 13.3%), orbit (1, 6.7%), bone (1, 6.7%), pharynx (1, 6.7%), 
and retroperitoneum (1, 6.7%). 
SBRT treatments were given over a median of 5 days (3-17 days). The 33 patients with hepatic 
metastases received 3-6 treatments of SBRT. Patients were treated with a median fraction dose of 10 Gy 
with a range from 4.5 to 14 Gy. The median total radiation dose provided to patients was 30 Gy with a 
range of 22.5-42 Gy. Patients either received 3 (81.1%) or 5 (18.9%) fractionations. The median BED was 
50 Gy (range 27-84 Gy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Local In SBRT Field Recurrence (Tables 2 and 3, Figure 1) 
Local recurrence was measured by local tumor progression within the SBRT field diagnosed on follow up 
CT scan. The median follow up for patients with local recurrence was 10.6 months (1.7-19.7 months) 
(Table 2). There were five lesions (13.5%) in five different patients that had local recurrence (Figure 1). 
The median time to recurrence was 10 months (2.6-13.1 months). The primary tumor location for patients 
with local recurrence was colorectal (40%), anal (20%), melanoma (20%) and ovarian (20%). This 
distribution was similar to the entire study population for colorectal and ovarian cancer (40% colorectal, 
12% ovarian, 9% melanoma, and 3% anal carcinoma).  
There was not a significant difference among patients with and without local recurrence when 
comparing median tumor size (4cm vs 4cm, 1.5 -13.9cm, p=0.216), pre-SBRT chemotherapy, primary 
surgical resection, or radiation. Many of the hepatic metastases were of larger size. Of the 5 local 
recurrences, three (60%) were in lesions less than 5cm in diameter (out of 23 lesions less than 5cm 
Table 2 Clinical Characteristics of Patients with Local Recurrence vs No Recurrence 
 Local Recurrence within  
SBRT Field (n=5) 
No Recurrence (n=9) 
Age (years) 59.5 (33.6-73.3)* 58.3 (44.8-82.3) 
Gender (male) 1 (20%) 5 (55.6%) 
Time from Diagnosis to SBRT (months) 17.6 (14.3-49.6) 47.3 (6.3-205.0) 
Time from Metastases Diagnosis to SBRT (months) 14.3 (4.3-29.7) 18.6 (4.3-109.0) 
Follow Up Length (months) 10.6 (1.7-19.7) 4.7 (1.2-23.5) 
Prior Primary Surgical Resection  4 (80%) 9 (100%) 
Prior Chemotherapy 4 (80%) 7 (77.8%) 
Prior Radiation 2 (40%) 3 (33.3%) 
Tumor Diameter (cm) 4 (1.5-13.9) 3 (1.5-5.3) 
Radiation Dose (Gy) 28.5 (25-36) 30 (25-36) 
Fraction Dose (Gy) 9.5 (5-12) 10 (5-12) 
Number of Fractions (3, 5) 3 (60%) 
2 (40%) 
6 (66.7%) 
3 (33.3%) 
*Median (Range) 
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overall) and therefore two local recurrences were in hepatic metastases greater than 5cm (out of 14 lesions 
greater than 5cm overall). There were 12 patients (36.4%) with metastases greater than 5cm in diameter 
that did not have local recurrence after SBRT, therefore the local recurrence rate for patients with 
metastases greater than 5cm was 14.3% (2 of 14 tumors). There were two patients with a tumor diameter 
greater than 10cm (11.5cm and 13.9cm), one had local recurrence after SBRT and one did not.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no significant difference in local recurrence rates based on number of fractions (p=0.362), 
radiation dose (p=0.534), or BED as compared to patients without any type of recurrence. The median 
dose for patients with local recurrence was 28.5 Gy with a BED of 46.3 Gy while the median dose for 
patients without recurrence was 30 Gy (25-36Gy) with BED of 50 Gy. Three patients (60%) who had local 
recurrence were treated with less than 30 Gy and radiobiological equivalent dose less than 50 Gy. 
Recurrence rate based on BED was 21.4% (3 of 14) for BED less than 50 and 8.7% (2 of 23) for BED 
greater than 50 Gy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Recurrence and Mortality in Patients with and without Cancer Progression 
 Follow Up Post-SBRT 
Follow Up Length (months) 8.1 (1.2-23.5)* 
Local Recurrence within SBRT Field (n=37) 5 (13.5%) 
Liver Out of SBRT Field Progression (n=33) 17 (51.5%) 
Systemic Metastases (n=33) 10 (30.3%) 
Any Recurrence (n=33) 25 (75.8%) 
No Recurrence (n=33) 8 (24.2%) 
Mortality (n=33) 18 (54.5%) 
*Median (Range) 
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Liver Out-Of SBRT Field Progression and New Systemic Metastases (Table 3)  
Seventeen patients (51.5%) progressed regionally within the liver, out of the SBRT field (Table 3). This 
was diagnosed on follow up CT scans as increased tumor volume outside of the SBRT field within the 
liver. The median follow up for patients who experienced out of field progression after SBRT was 7.4 
months (1.4-20.1 months). There was a median time period from SBRT to recurrence of 5.1 months 
(0.8-17.5 months). 
Ten patients (30.3%) had systemic recurrence in the following locations: lung (4), sternum (2), spine 
(1), brain (1), biliary system (1), and peritoneal implants (1). The median follow up period for patients 
who had systemic metastases after receiving SBRT was 10.6 months (6.5-21.1 months). Patients with 
systemic recurrence had a median time period from SBRT to recurrence of 5.1 months (2.2-15.6 months). 
Both populations of patients who had out of field recurrence and systemic recurrence had similar 
pre-SBRT primary surgical resections, chemotherapy, and radiation rates. Additionally both had similar 
median radiation doses, fraction doses, and number of fractions. 
Survival after SBRT for Hepatic Metastases (Table 3, Figure 2) 
The Kaplan-Meier survival curve of patients after SBRT is reported in Figure 2. The overall survival rate 
was 45.5% (15 of 33 patients) at 23.5 months with a median survival of 10.6 months. Univariate analysis 
demonstrated an increase in mortality in patients who had local recurrence within the SBRT field, regional 
out-of-field progression, and systemic recurrence (40%, 58.8% and 80%). As would be expected, there 
was a mortality difference, although statistically not significant, between patients with any recurrence 
(60%) versus patients without recurrence (25%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxicities Secondary to SBRT for Hepatic Metastases (Table 4) 
There were no grade 4 or 5 adverse events secondary to SBRT. Complications and toxicities secondary to 
SBRT are reported in Table 4. The most common complaint after SBRT was pain in 7 patients (21.2%) 
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followed by nausea without emesis in 5 patients (15.2%). There were not any patients that reported 
diarrhea or gastrointestinal distress. There was one patient who experienced an asymptomatic elevation of 
her liver laboratories. Wilcoxon Rank Sum Test did not reveal significant changes in total bilirubin 
(p=0.687), alkaline phosphatase (p=0.151), or albumin (p=0.716) before and after SBRT. There were not 
any patients that experienced liver failure.  
 
Table 4 Complications and Side Effects Post SBRT (n=33) 
 Short Term Follow Up Post-SBRT 
Follow Up (Months) 8.1 (1.2-23.5) * 
Nausea 5 (15.2%) 
Diarrhea 0 (0%) 
Pain 7 (21.2%) 
Elevated Liver Laboratories 1 (3.0%) 
Liver Failure 0 (0%) 
*Median (Range) 
 
Discussion 
While surgical resection of liver metastases remains standard treatment and may provide clinical benefits 
and prolonged survival [3, 4], most patients with metastatic cancer to the liver are not candidates for 
resection [12]. Non-resectional ablative therapies including cryotherapy, microwave ablation, and 
radiofrequency ablation, may provide better local control in patients not amenable to surgical resection 
[13]. Although these ablative therapies may impact the natural history of the disease with potentially less 
morbidity [13], they are limited by the size and location of the hepatic metastasis [22-26]. Ablative 
therapies can be offered through percutaneous and minimally invasive approaches, however not all 
metastases are accessible through these techniques. As chemotherapeutic and targeted agents improve, 
there may be an increasing population of patients who may benefit from liver directed therapy. SBRT 
allows for the delivery of high radiation doses to liver metastases while limiting the toxicity to the normal 
liver parenchyma found with standard EBRT techniques. 
Chang et al retrospectively reviewed 65 patients with colorectal cancer with 102 hepatic metastases 
who were treated with SBRT at a median dose of 42 Gy (22-60 Gy) [40]. They found a 29% in field 
recurrence rate and a 45% overall survival rate after a 24 month period. These patients tolerated SBRT 
well without any grade 4 or 5 complications [40]. Scorsetti et al published a phase II study of 61 patients 
and 76 lesions treated with a median dose of 75 Gy in three fractions (BED 218 Gy). They had an in-field 
recurrence rate of 5.3% (4 lesions) and only one grade 3 toxicity (chest wall pain) [41]. 
Similar to other studies, we found that SBRT can be delivered safely to patients with hepatic metastases 
[40-42]. SBRT was well tolerated by the patients with few clinical complications, without any statistically 
significant change in hepatic laboratory values, and without any grade 4 or 5 toxicities. In this case series, 
there were no cases of liver failure despite a median dosage of 30 Gy of radiation. While 21.2% 
experienced pain and 15.2% experienced nausea secondary to SBRT, all patients returned to receive 
radiation over multiple fractions and completed their treatments.  
Local recurrence after SBRT only occurred in five patients (13.5%). While this rate of local recurrence 
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is higher than some rates reported for radiofrequency and microwave ablative therapies [43, 44], this 
patient population included patients with larger tumors for which standard ablative therapies have higher 
recurrence rates and some patients who were not candidates for ablative therapy due to lesion location. It 
is also of interest we found similar local recurrence rates (14.3%) in larger lesions greater than 5cm. 
These patients with larger lesions are not ideal candidates for other liver directed therapies.  
Combining our results with those of others, there is a clear trend that higher SBRT doses result in 
improved local control [40-42]. Although not statistically significant secondary to the small patient 
population, we found higher local control with a BED higher than 50 Gy. It is unclear what the ideal dose 
should be or where the local control curve plateaus. Our current practice is to use a BED of at least 80 Gy 
(five fractions of 10 Gy) and our preference is 60 Gy in three fractions (BED 150 Gy). 
Our study population included many patients with advanced disease. In this study, 45.5% of patients 
had extra-hepatic disease prior to SBRT. These patients were likely preselected by their clinicians for 
SBRT because the extent of their liver metastases would have a significant impact in the morbidity and 
natural history of their disease. Despite the advanced disease in this heavily pre-treated population, the 
one year overall survival of this patient population was 45.5%. 
While the limited hepatic toxicity and side effects are encouraging, there are study limitations. This is a 
case series examined retrospectively from a single institution with potential weaknesses inherent in this 
design. Larger patient numbers and a longer follow-up period in a prospective study are required to better 
assess the safety of this therapy. Additionally, this study included patients with different types of primary 
cancers and SBRT may have different radio-sensitivities depending on the primary tumor.  
Conclusion 
SBRT is safe and well tolerated in patients with hepatic metastases. SBRT offers a potential local therapy 
to patients with metastatic disease in the liver with minimal toxicities. The non-invasive nature of SBRT 
and the ability to treat lesions of various sizes and locations has significant appeal to patients and 
practitioners. This therapy may fill a role for patients with lesions not amenable to traditional ablative and 
surgical techniques or regional treatment in patients with extra-hepatic disease.  
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